A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908)

No abstract is available for this paper.

• Publication year

  2016

• Venue

  American journal of hematology/oncology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.24265PMID 26662208PMCID PMC4806550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

  2015cited by this paper
• Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.

  2015cited by this paper
• Phase II study of alemtuzumab–rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes

  2015cited by this paper
• Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

  2015cited by this paper
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

  2014cited by this paper
• rogressive multifocal leukoencephalopathy complicating untreated hronic lymphatic leukemia : Case report and review of the literature ranziska

  2014cited by this paper
• Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies

  2014cited by this paper
• Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab

  2014cited by this paper
• Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

  2014cited by this paper
• Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

  2014cited by this paper
• Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

  2013cited by this paper
• Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.

  2012cited by this paper
• Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia

  2012cited by this paper
• Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

  2012cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Rituximab-associated neutropenia.

  2010cited by this paper
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2010cited by this paper
• Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

  2010cited by this paper
• Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab

  2009cited by this paper
• Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.

  2009cited by this paper
• Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximab

  2008cited by this paper
• Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia : A Report from the International Workshop on Chronic Lymphocytic Leukemia ( IWCLL ) updating the National Cancer Institute-Working Group ( NCI-WG ) 1996 guidelines

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

  2007cited by this paper
• Have we forgotten the purpose of phase III studies?

  2007cited by this paper
• The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes1

  2006cited by this paper
• Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy

  2006cited by this paper
• Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia1

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

  2005cited by this paper
• Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1

  2004cited by this paper
• A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

  2004cited by this paper
• Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

  2003cited by this paper
• Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

  2002cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• Guidelines

  1994cited by this paper
• The randomization and stratification of patients to clinical trials.

  1974cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls

  2023cites this paper
• FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis

  2022cites this paper
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 4.2020

  2020cites this paper
• JC Polyomavirus Infection Potentiated by Biologics.

  2020cites this paper
• Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.

  2020cites this paper
• The secret afterlife of platelets

  2019cites this paper
• Six-packed antibodies punch better

  2019cites this paper
• Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies

  2018cites this paper
• Advances in chronic lymphocytic leukemia pharmacotherapy.

  2018cites this paper
• Monoclonal antibody therapy in chronic lymphocytic leukemia

  2018cites this paper
• Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity

  2017cites this paper
• Engineering sensor proteins for antibody detection by design and evolution

  2017cites this paper
• Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia

  2016cites this paper
• Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

  2016cites this paper
• Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.

  2016cites this paper